safety of glp 1 receptor agonists GLP-1 are increasingly used before pregnancy, but data have been limited., This meta-analysis pooled data from nearly 37,000 pregnancies and found no increased risk major Safety-focused summary of GLP-1 receptor
Description
Despite these insights, the incidence of clinically significant muscle wasting attributable to GLP-1RA therapy remains undefined

About half think the medication should be affordable and covered by insurance

Comparative effectiveness of glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitors, and sulfonylureas on the risk of dementia in older individuals with type 2 diabetes in Sweden: an emulated trial study

To date, several small molecule DPP-4 inhibitors (vildagliptin, sitagliptin, saxagliptin, lina-gliptin, and alogliptin) have been used as treatments for type 2 diabetes to improve glucose tolerance

In Proc

There was no difference in risk for AF between GLP-1RA and SGLT2i